Generalized Pustular Psoriasis Market Overview
Global Generalized Pustular Psoriasis Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2024-2031.
Generalized Pustular Psoriasis (GPP) is one of the rare and severe forms of pustular psoriasis. It is also termed von Zumbusch psoriasis. Women are more susceptible to the condition especially pregnant women which is termed impetigo Herpetiformis. Plaque psoriasis is one of the significant risk factors for developing the condition GPP.
It generally affects the hands and soles of the feet which arises suddenly with wide-spread bumps all over the legs. There is no cure for GPP, the treatment only helps to reduce the flares and severity which prevents from worsening the condition further.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Treatment, Route of Administration, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | Asia-Pacific |
| Fastest Growing Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing clinical trials
Increasing ongoing clinical trials on generalized pustular psoriasis due to the increasing prevalence and advancements in drug development strategies drive the GPP market in the forthcoming period. For instance, in October 2023, AnaptysBio, Inc. released positive top-line results from its global phase 3 GEMINI trial evaluating the safety and efficacy of imsidolimab (Interleukin).
According to clinicaltrails.gov, Shanghai Huaota Biopharmaceutical Co., Ltd. is conducting a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP) which is in Phase I.
Pfizer is also conducting a clinical trial to evaluate the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use. The study start date is October 21, 2019. The estimated completion date is May 12, 2025.
Side effects of psoriasis drugs
Side effects of drugs include high temperature, night sweats, swollen lymph nodes, shortness of breath and swelling of ankles or feet could be initial signs of heart failure. Mild symptoms are very common after taking a few drugs.
Market Segment Analysis
The global generalized pustular psoriasis is segmented based on treatment, route of administration, end-user and region.
The TNFα antagonists segment accounted for approximately 67.4% of the market share
TNFα antagonists are first-line therapy for psoriasis disease including all the types of psoriasis. TNF inhibitors (TNFI's) infliximab, and adalimumab are FDA-approved medications for different types of psoriasis. Recent FDA approvals for biosimilar versions of adalimumab increase the usage in the treatment of generalized pustular psoriasis. For instance, in March 2023, Sandoz received FDA approval for its citrate-free, high-concentration formulation (HCF) of its adalimumab biosimilar, Hyrimoz.
In March 2023, Celltrion USA received the US Food and Drug Administration (FDA) approval for the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation. Furthermore, Amgen’s Amjevita was the first one ever launched at the end of January 2023; Hyrimoz which is also a biosimilar of adalimumab along with the others were launched starting in July 2023.
Market Geographical Share
North America accounted for approximately 41.5% of the market share in 2022
North America is expected to hold the largest share of the market due to the prevalence of generalized pustular psoriasis.
According to Boehringer Ingelheim publication, recent estimates show the prevalence of around 9 per 100,000 in Sweden and the US combined and around 3 per 100,000 in Japan. Although the count is very low, the prevalence is observed in the US and other countries due to the rarity.
Due to the presence of key players in the market such as Johnson & Johnson, Bristol Myers Squibb, and Pfizer Inc., etc. which are American pharmaceutical companies that are currently focused on research and development of drugs and therapies for the treatment of generalized pustular psoriasis.
COVID-19 Impact Analysis
COVID-19 impact is very low on generalized pustular psoriasis due to the rarity of the disease. Due to the implementation of lockdowns, stoppage of several services was seen which did not influence the treatment of GPP. The supply of drugs has been interrupted by the strict guidelines implemented during the COVID-19 pandemic which did not have much impact on the generalized pustular psoriasis market.
Competitive Landscape
The major global players in the generalized pustular psoriasis market include Bristol Myers Squibb, UCB, Inc, Pfizer Inc., AbbVie Inc., Novartis AG, Astellas Pharma Inc., Eli Lilly and Company, Amgen Inc., Johnson & Johnson, AstraZeneca among others.
Key Developments
- In September 2022, Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.
- In May 2023, Boehringer Ingelheim held ceremonies to launch the world's first biologic agent to treat generalized pustular psoriasis (GPP) in China.
Why Purchase the Report?
- To visualize the global generalized pustular psoriasis market segmentation based on treatment, route of administration, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of generalized pustular psoriasis market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global generalized pustular psoriasis market report would provide approximately 58 tables, 61 figures, and 185 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
